This is the authors' abstract. We don't add key points for this paper.
We analyzed nationwide IQVIA pharmacy buprenorphine prescription episodes to characterize patterns, prescribers, and payers of long-acting injectable buprenorphine during the period 2021-24. Among 2,266,202 episodes, 41,488 (1.83 percent) were identified as being initiated with long-acting injectables, varying greatly across states. By 2024, Medicaid emerged as the most likely payer (71 percent of episodes), and most long-acting injectable episodes were prescribed by advanced practice clinicians such as nurse practitioners (62 percent).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: